Many patients with high-risk gastrointestinal stromal tumors (GIST) wonder if taking their medication longer helps. This study looked at 75 patients who had surgery and then took Imatinib for either more than three years or three years or less. The goal was to see if the longer treatment time made a difference in stopping the cancer from coming back.
After five years, those who took the drug longer had slightly better relapse-free survival rates compared to the shorter group. However, when researchers adjusted for other factors, the extra time on medication did not significantly improve survival outcomes. Overall survival rates were the same for both groups.
The study also checked drug levels in the blood but found the meaning of those numbers is still unclear. Because this was a look back at past records, the results need to be checked in new, forward-looking studies before changing how doctors treat patients today.